title: From target therapy to miRNA therapeutics of human multiple myeloma: theoretical and technological issues in the evolving scenario.
abstract: The progress in the understanding of biological events underlying multiple myeloma (MM) development and progression has allowed the design of molecularly targeted therapies (MTTs) for this disease and several new compounds are presently under investigation in the preclinical and clinical settings. The recent discovery that miRNAs, and short non coding RNAs in general, are involved in the pathogenesis of cancer has raised the issue whether a novel therapeutic approach should be provided by selective interference with miRNA network. This review will focus on the rationale of miRNA-based therapeutics, providing the most relevant information on biogenesis and technical issues in miRNA analysis. Finally, a detailed overview of the recent findings on miRNA therapeutics of MM will be discussed.
authors.affiliation: Department of Experimental and Clinical Medicine, Magna Graecia University and Medical Oncology Unit, T. Campanella Cancer Center, Salvatore Venuta University Campus, Catanzaro, Italy.
authors.forename: Marco
authors.initials: M
authors.lastname: Rossi
authors.forename: Nicola
authors.initials: N
authors.lastname: Amodio
authors.forename: M T
authors.initials: MT
authors.lastname: Di Martino
authors.forename: Daniele
authors.initials: D
authors.lastname: Caracciolo
authors.forename: Pierosandro
authors.initials: P
authors.lastname: Tagliaferri
authors.forename: Pierfrancesco
authors.initials: P
authors.lastname: Tassone
mesh_terms: D000818:Animals; D001853:Bone Marrow; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D035683:MicroRNAs / Q000037:antagonists & inhibitors / Q000235:genetics* / Q000378:metabolism / Q000627:therapeutic use*; D058990:Molecular Targeted Therapy; D009101:Multiple Myeloma / Q000235:genetics* / Q000628:therapy*
chemical_list: D035683:MicroRNAs